Kornimate/medical-research-clean huggingface dataset:
repetitive split-belt treadmill perturbation in children with unilateral cerebral palsy

Conditions: Cerebral Palsy

Summary: this study was designed to investigate the effect of repeated split-belt treadmill waking practice on gait symmetry, dynamic balance control, and locomotor capacity in adolescents with unilateral cerebral palsy (ulcp). fifty-two children with ulcp were randomly allocated to the split-belt treadmill walking (n = 26; undergone split-elt treadmill training or the control group (n =23, received standard rehabilitation program). both groups were assessed for gait symmetry, dynamic balance control, and locomotor capacity pre and post-treatment.

fifty-two children with ulcp were recruited from the physical therapy outpatient clinic of the college of applied medical sciences, prince sattam bin abdulaziz university, king khalid hospital, and a tertiary referral hospital, al-kharj, saudi arabia. their age ranged between 10 and 16 years, were functioning at levels i or ii according to the gross motor function classification system, and had spasticity levels 1 or 1+ per the modified ashworth scale. children were excluded if they had fixed deformities, underwent neuromuscular or orthopedic surgery in the last 12 months, submitted to botox injection in the past 6 months, had attentional neglect, and if they had cardiopulmonary problems that could be exacerbated by exercise. outcome measures 1. gait-symmetry indices: gait symmetry indices (spatial and temporal) were measured through the portable gaitrite system. 2. dynamic balance: the directional dynamic limit of stability (forward, backward, paretic, and non-paretic) and overall limit of stability were assessed using the biodex balance system. 3. locomotor capacity: this was assessed through the 6-minute walk test (6-mwt), the timed up and down stair test (tuds), and the 10-meter shuttle run test (10msrt). both groups were trained for one hour, three times a week, for 12 successive weeks. the split-belt treadmill walking group performed repetitive split-belt treadmill training with an error-augmentation strategy (i.e., exaggeration of the initial step-length asymmetry). the control group received the standard rehabilitation program, which comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.

Eligibility criteria:
inclusion criteria: * unilateral cerebral palsy * age 10-16 years * motor function level i or ii according to the gross motor function classification system. * spasticity level 1 or 1+ according to the modified ashworth scale exclusion criteria: * structural deformities/contractures * musculoskeletal or neural surgery in the last year * botox injection in the last 6 months. * cardiopulmonary disorders that could be exacerbated by exercise. * perceptual and/or behavioral disorders.
nasal administration of dexamethasone for multiple sclerosis (ms) treatment

Conditions: MS Patient With Relpasing Remitting Attacks

Summary: the study aims to assess the safety and efficacy of nasale administration of dexamethasone in relapsing ms patients


Eligibility criteria:
inclusion criteria: * ms patients with esatblished relapsing remitting attacks * increase in edss of at least 1 point for a least one day exclusion criteria: * children under 18 * pregnant patients * patients with diabetes * known allergy to steroids * patients who received steroids within 3 months prior to the study

Keywords: multiple sclerosis, relapsing remitting, dexamethasone
a prospective randomized controlled trial on the use of bone morphogenetic 7 (bmp-7) (op-1®) and demineralized bone matrix in tibial non-union

Conditions: Non-union Diaphysary Tibial Fractures

Summary: the researchers propose a prospective, randomised partially-blinded study to investigate the clinical and radiological outcome, effect on quality of life and socio-economic impact of non-union of diaphysary tibial fractures treated with bmp-7 in adjunct to fresh frozen allograft, in comparison to treatment with allograft together with dbm (demineralised bone matrix).


Eligibility criteria:
inclusion criteria: * diaphysary tibial non-unions will be included (9 months after first surgery) * major surgery includes exchange nailing, bone grafting, internal fixation, amputation and soft-tissue coverage procedures, such as delayed primary closure and free flaps * surgery is classified as minor for removal of external fixator pins for local infection and removal of a static locking screw from intramedullary nails, a procedure known as dynamization * asa 1 and asa 2 * gap length/bone contact detected (1-5 cm): largest cortical gap in any radiographic incidence * subject or legal guardian is willing and able to understand, sign and date the study specific patient informed consent, which has been approved by the institutional review board * agrees to participate in post-operative evaluations and required rehabilitation regimen exclusion criteria: * patients with known hypersensitivity to the active substance or collagen * gap more than 5 cm * immature skeleton * known auto-immune disease, including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sjögren's syndrome and dermatomyositis/polymyositis * active infection on unhealed site or active systemic infection * non-healing resulting from pathological fractures, tumours or metabolic bone diseases * presence of tumour in vicinity of non-union * patients receiving chemotherapy, radiotherapy or immunosuppressant treatment or excessive steroids * patients with severely compromised soft tissue coverage or vascularisation at the non-union site, sufficient to impair bone healing * patients with congenital non-union * pregnancy and lactation * non-union of multiple bones interfering with walking * patients with neuromuscular diseases or conditions interfering normal weight bearing * patients who, judged by the surgeon, are candidates for just internal fixation alone
the study of blood pressure variability to impact arterial stiffness and carotid atherosclerosis

Conditions: Carotid Atherosclerosis

Summary: the purpose of this study is to investigate whether and what extent blood pressure variability is associated with arterial stiffness and carotid atherosclerosis, furthermore to compare the difference in the relationship of the types of blood pressure variability with arterial stiffness and carotid atherosclerosis.


Eligibility criteria:
inclusion criteria: * can step by himself/herself exclusion criteria: * cardiovascular and cerebrovascular diseases * secondary hypertension * chronic cardiac, renal, gastro-intestinal, pulmonary or any other systemic disease process requiring chronic intake of prescription medications
effect of mindfulness based treatment for obsessive-compulsive disorder

Conditions: Obsessive-compulsive Disorder

Summary: hypothesis of this study is that mindfulness meditation would decrease the severity of obsessive-compulsive symptoms.

before and after 8 weeks of mindfulness program, we will measure y-bocs scores in ocd patients. as a control program, relaxation and psychoeducation will provided to ocd patients.

Eligibility criteria:
inclusion criteria: * obsessive-compulsive disorder * age 17-55 exclusion criteria: * currently undergoing cognitive behavioral therapy, psychotherapy * other medical disease

Keywords: obsessive-compulsive disorder mindfulness meditation
bone healing accelerant (bha) versus autologous bone grafting (abg) for hindfoot or ankle arthrodesis

Conditions: Foot Deformities

Summary: this study is being conducted to demonstrate the safety and effectiveness of bone healing accelerant (bha) product when applied to the joint space of the ankle of hindfoot (the section of the foot immediately below the ankle joint) during fusion surgery. it is hypothesized that by 6 months, the number of subjects with successful bone fusion will be greater in the bha-treated group compared to subjects treated with standard of care alone.


Eligibility criteria:
inclusion criteria: * patient has pain with weight-bearing in the joint(s) below that, in the opinion of the investigator, warrants arthrodesis: 1. tibiotalar (ankle) 2. talocalcaneal (subtalar) 3. talonavicular 4. calcaneocuboid 5. double hindfoot (e.g., talonavicular and talocalcaneal joints) 6. triple hindfoot (subtalar, talonavicular and calcaneocuboid joints * joint space(s) can, in the opinion of the investigator, be adequately filled with no more than 9 cc of graft material (bha or abg) * each fused joint can be adequately compressed and rigidly stabilized with plates, screws, staples or a combination thereof. external fixation, percutaneous kirschner wires or intramedullary rods may not be used. * patient is willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations. * if patient is a woman of childbearing bearing potential (not post-menopausal for 12 months or surgically sterile), patient has a urine pregnancy test with a negative result at screening and on the day of surgery, prior to the procedure. these trial participants must commit to adequate birth control through the 52-week follow-up exclusion criteria: * skeletally immature patients (i.e., radiographic evidence of open physes), regardless of age * bone deficit, defect or void requiring a structural graft * condition requiring intramedullary nailing or external fixation for the arthrodesis * condition requiring osteotomy or fusion of any midfoot joints. * prior arthroplasty, arthrodesis, major surgical repair or reconstruction of the index ankle or hindfoot joints.
dose-finding study to assess the safety and effect of syl1001 in patients with ocular pain

Conditions: Ocular Pain; Dry Eye Syndrome

Summary: the aim of this pilot study is to compare the analgesic effect of two strengths of syl1001 eye drops versus placebo in patients with ocular pain associated with dry eye syndrome. general and local tolerability are also evaluated.


Eligibility criteria:
inclusion criteria: * give written informed consent to participate in the study, after having received all information relating to the design, aims and possible risks resulting therefrom. * common symptoms of persistent, daily, mild to moderate dry eye lasting more than three months: osdi scale between 13-70 and vas scale between 2 -7. * eye tests in both eyes: corneal fluorescein staining (oxford scale \> 0), tear break-up time \< 10 seconds and schirmer's test with anaesthesia \< 10 mm/5min. exclusion criteria: * women who are pregnant or breastfeeding or who have a positive urine pregnancy test. women who do not commit to use a medically acceptable method of contraception from the time of selection and throughout the study. * any current, relevant disease, including respiratory disease, cardiovascular disease, endocrine disease, neurological disease, haematological disease, kidney disease, oncological disease, liver disease, gastrointestinal dysfunction, hypertension or active acute infectious processes. * previous chronic or recurrent processes which, according to the investigator, could affect the development of the study. * concomitant use of other medications with analgesic activity by any route of administration at the time of entry into the study. * change in any concomitant eye and/or systemic medication of the patient one month before the study and during the study. * changes in the pre-established administration schedule of artificial tears during the 15 days before the study and during the 10 days of the study. * initiation of treatment with cyclosporine or changes in the dosage or administration schedule of cyclosporine within the 6 months before inclusion in the study. * history of hypersensitivity to drugs. * use of contact lenses during the treatment and previous 15 days. * history of drug abuse or drug or alcohol dependence. * laboratory abnormalities which, in the investigator's opinion, are clinically significant. * previous refractive surgery. * having participated in another clinical trial within the 2 months prior to inclusion. * another eye disease that is significant in the investigator's opinion.
the prevention and treatment on obesity and weight management by oral supplementation of probiotics and prebiotics

Conditions: Overweight and Obesity

Summary: the goal of this interventional study is to test whether consumption of wonderlab probiotics with prebiotics could improve obesity and overweight in chinese people who are aged 25-45 and overweight. the main question it aims to answer is: - whether the weight of participants can be lost after 10 weeks' intervention 150 participants will be randomized into 3 study groups (50 each group) in the two study sites, who will consume assigned product according to instructions for 10 weeks. three site visits will be made for each participant and all relevant clinical data will be captured and recorded into ctms(clinical trial management system) for statistical analysis. researchers will compare the three groups to conclude whether the wonderlab study product can improve obesity and overweight over placebo product.


Eligibility criteria:
inclusion criteria: * chinese males or females, age between 25-45; * overweight population: bmi 24-27.9 \& obesity population: bmi \>=28; * blood lipids in high potential risks but without medication:tg \> 5mmol/l or ldl \>= 3.4 mmol/l or tc \>= 5.2 mmol/l. * understand the test procedure, read, and sign an appropriate informed consent form indicating their willingness to participate; * agree to avoid medication treatment for weight management, including blood lipids and sugar control. exclusion criteria: * have used any medication for weight management at least one month before this study. * subject having done plastic surgery for weight management. * be involved in any aspect of test administration, i.e., evaluating or overseeing activities related to product. * have participated in any clinical study involving the test sites within the previous 6 months, or is subject participating in any clinical study concurrently. * have a history of any type of metabolic syndrome, including but not limited to any type of diabetes, obesity and heart disease. * have a history of any disease or the presence of health condition on the study sites that the investigator feels would interfere with the study. * be taking antihistamines (\> 3x/week) or anti-inflammatory (\> 8x/week) on a regular basis, or has the subject taken systemic or topical steroidal medications within 4 weeks of study enrolment. * have any of the following conditions or factors that the investigator believes may affect the response of the skin or the interpretation of the test results, including, but not limited to, pregnancy, lactation and hepatitis. * have any cuts/abrasions on the test site at baseline. * the subject is an employee of sponsor or the site conducting the study.

Keywords: probiotics prebiotics wonderlab
effects of lower body positive pressure in people with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the goal of this clinical trial is to compare effects of retro walking exercise versus forward walking using lower body positive pressure on knee pain, physical function, and quadriceps muscle strength in people with mild to moderate knee oa. the secondary aim is to compare effects of retro walking exercise versus forward walking using lower body positive pressure on mobility function, balance, and self-reported health outcomes in people with mild to moderate knee oa. the main questions it aims to answer are: * does retro walking exercise improve knee pain, physical function and quadriceps muscle strength compared to forward walking exercise using lower body positive pressure in people with mild to moderate knee osteoarthritis? * does retro walking exercise improve mobility function, balance, and self-reported health outcomes compared to forward walking exercise using lower body positive pressure in people with mild to moderate knee osteoarthritis? participants will walk (retro versus forward) on a lower body positive pressure treadmill. if there is a comparison group: researchers will compare \[retro walking compares to forward walking\] to see if \[improve in knee pain, physical function, and quadriceps muscles strength\]


Eligibility criteria:
inclusion criteria: * mild to moderate knee osteoarthritis * edge bigger or equal 40 years * knee pain reported by participants in the past 30 days * one or both knees osteoarthritis graded with kellgren \& lawrence grade 1 - 3 exclusion criteria: * if they didn't meet the inclusion criteria * history of hip, knee or ankle injury or surgery within the last year * kellgren \& lawrence grade \> 3 of severe knee oa * diagnosed with rheumatoid arthritis * history of knee injection with any medicine that reduce pain within the last year * history of other medical condition that would disturb normal walking function * receive physical therapy in the last three months * pregnant * other conditions that are contra indication to lower body positive pressure.
changes and associations between cervical range of motion, pain, tmj range of motion and quality of life in migraineurs applying physical therapy

Conditions: Migraine; Temporomandibular Joint Disorders; Myofascial Trigger Point Pain

Summary: the purpose of this study is to assess the effects of physiotherapy program and review the associations between neck movements, pain, temporomandibular joint (tmj) movements and quality of life in individuals with migraine.

migraine is one of the most common type of headaches in the world causing the greatest disability in individuals under 50 years of age. many different health organizations (american headache society etc.) recommend regular physical activity and exercise for the treatment and prevention of migraine. however, the relationship between aerobic exercise and migraine is still not completely clear. unfortunately, a research database to validate the benefits of exercise for people with migraine is still being developed. the aim of this study is to assess the effects of physiotherapy program and review the associations between neck movements, pain, temporomandibular movements and quality of life in individuals with migraine. the study was approved by committee on biomedical research ethics of kaunas region (2020-06-30 no.bec-sr(m)-266).

Eligibility criteria:
inclusion criteria: * individuals diagnosed with migraine 2 or more years ago * headache, occurring at least 6 times a year * individuals from 18 years of age * voluntary patient consent to participate in the study exclusion criteria: * neurological or psychiatric disorder * visiting an orthodontist, taking muscle relaxants * head or neck injury, cervical spine hernia, facial or temporomandibular injury
a study of the safety, tolerability, pharmacokinetics and pharmacodynamics of pf-04629991 in healthy volunteers

Conditions: Healthy Volunteers

Summary: this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of pf-04629991 in healthy subjects. dose exploration will proceed in a step-wise manner, beginning with low doses not expected to have significant biological effects and proceeding to doses approximating or exceeding the anticipated therapeutic level. doses to be explored may be limited by tolerability, and will not exceed levels previously shown to be tolerable in animals.


Eligibility criteria:
inclusion criteria: * healthy non-smoking men and women * body mass index 18-30 kg/m2 exclusion criteria: * women must not be able to have children * no current infections

Keywords: rheumatoid arthritis first in human safety pharmacokinetics pharmacodynamics
a phase 2 study to evaluate the safety, efficacy and pk of tildacerfont in children with cah

Conditions: Congenital Adrenal Hyperplasia; 21-OHD

Summary: an investigation of the safety and efficacy of tildacerfont in participants with cah.

this is a study to evaluate the safety and efficacy of tildacerfont in participants with congenital adrenal hyperplasia (cah). treatment will consist of 4 or 12 weeks of continuous dosing followed by safety follow up.

Eligibility criteria:
inclusion criteria: * male and female subjects aged 2+ * diagnosis of cah due to 21-hydroxylase deficiency (ohd) and/or elevated 17- hydroxyprogesterone (ohp) requiring ongoing gc replacement since diagnosis * stable dose of gc replacement for at least 1 month prior to screening exclusion criteria: * history of bilateral adrenalectomy or hypopituitarism * clinically significant unstable medical conditions, illness, or chronic diseases * history of active bleeding disorders * females who are pregnant or nursing

Keywords: pediatric cah adrenal disorder congenital adrenal hyperplasia
a study to investigate the safety, tolerability, and pharmacokinetics of azd7503 in japanese healthy participants.

Conditions: Heathy Participants

Summary: the study will evaluate the safety, tolerability, and the pharmacokinetics (pk) of azd7503 following multiple subcutaneous doses in healthy japanese participants.

this is a phase i, randomised, single-blind, placebo-controlled study. the healthy japanese participants will receive randomly (3:1) either azd7503 or placebo subcutaneously. the study will comprise of: * a screening period of 28 days. * randomization on day 1. * a 9-week treatment period. dose 1 will be administered on day 1. dose 2 will be administered at the study site on day 29. dose 3 will be administered on day 57. * a follow-up period of 10 week after last dose of study intervention. * the total duration of the study will be 23 weeks.

Eligibility criteria:
inclusion criteria: * for japanese participants: a japanese participant is defined as having both parents and 4 japanese grandparents as confirmed by the interview. this includes second and third generation japanese whose parents or grandparents are living in a country other than japan. participants must have suitable veins for cannulation. * females must be of non-childbearing potential. * males and females must adhere to the contraception methods. * have a body mass index between 18 and 30 kg/m2 inclusive. exclusion criteria: * history of any clinically significant disease or disorder in the investigator's opinion. * history or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * any clinically important illness, medical/surgical procedure or trauma. * any abnormal laboratory values, clinical chemistry, hematology or urinalysis results, vital signs, electrocardiography. * any clinically significant cardiovascular event. * participants with known autoimmune disease or on-treatment with immune-modulatory drugs. * any positive result at the screening visit for serum hepatitis b surface antigen, hepatitis c antibody and human immunodeficiency virus. * confirmed covid-19 infection during screening as per local guidelines. * history of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity. * use of any prescribed or nonprescribed medication. * history of major bleed or high-risk of bleeding diathesis. * any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention. * participants who have previously received azd7503 or any investigational drug targeting hsd17b13. * vulnerable participants.

Keywords: non-alcoholic fatty liver disease cirrhosis n-acetyl galactosamine-conjugated antisense oligonucleotide hsd17b13 protein